Biotech Leaders


Biotech Leaders Agenda

Tuesday 10 May 2022
(All times in GMT)


Welcome Address

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX


Biotech in 2022: Another wave or a low tide?

  • Review the 2021 biotech year in numbers: How much funding did the sector attract? How did the IPO market evolve? What are trends on the stock market?
  • Deep-dive on external innovation: How do we see external innovation landscape evolve? What assets and companies are most successful?
  • Looking ahead: What does this mean for 2022 and beyond?

Alexandra Zemp, Partner, McKinsey

Alexandra Zemp, Partner, McKinsey

 


The Next Phase Of Europe’s Booming Biotech Ecosystem – Building Global Biotech Leaders, Financing Next Wave Innovation And Joining The Dots Between Clusters

After the shock in early 2020, the biotech ecosystem rebounded quickly and Europe was very much at the forefront of solving a the biggest global challenge in decades. As we enter the post-pandemic era, the European ecosystem has never been stronger with more capital, talent and experience and an ever-growing and more robust balance of early, growth and established companies. Executives of Europe’s leading life biotech companies, investors and key stakeholders discuss the next phase, working in a pan-European collaborative strategy to translate innovation, and continue to strategically build an ever-stronger globally competitive powerhouse.

  • How and why has Europe survived and thrived? What are the next steps for continued sustainable growth of the whole ecosystem?
  • Is access to talent and experience to drive companies becoming easier with the move to a more digital world with amounts of remote working?
  • Accessing the US market and building a transatlantic footprint is still ever critical, but in what ways is Europe leading the way?
  • With more capital in the space, both with larger private investment rounds and on the buoyant public markets, are companies able to build a longer-term vision? Has there been a cultural shift?

Werner Lanthaler, CEO, Evotec 
Brad Robling, VP Corporate Business Development, Eli Lilly 
Debbie Harland, Venture Partner, SROne 
Andrew Hack, Managing Director, Bain Capital Life Sciences 
Graziano Seghezzi, Managing Partner, Sofinnova 

Werner Lanthaler, CEO, Evotec    Brad Robling, VP Corporate Business Development, Eli Lilly    Deborah Harland, Partner, SR One    Andrew Hack, Managing Director, Bain Capital Life Sciences    Graziano Seghezzi, Managing Partner, Sofinnova


Capital Markets & Investment


Leading The Way In The Global Investment Landscape - New Strategies, Competition And Syndication

The numbers paint a picture of a booming investment market but the how, where and why of this capital influx are nuanced. And while total deal values for European biotechs have increased, the increase in the US has been higher still, and US investors are increasingly participating and being a driver in larger investment rounds in European companies. The larger and more established funds continue to attract the largest pools for news funds and vehicles and are finding new ways to help their portfolio companies grow. Leading investors discuss the global investment landscape and the part being played by Europe’s growth and maturation, as well as what they expect 2022 and onwards to hold.

  • Is competition for deals higher than ever?
  • Could de-fragmented and re-invigorated European public markets help the maturing ecosystem further and compete with US public markets?
  • Evolution of funding vehicles and mandates – early stage, growth, crossovers, SPACs

Moderator: William Hicks, Co-chair Securities & Capital Markets Group, Mintz
Sofia Ioannidou, Partner, Andera Partners
Stephanie Sirota, Partner and CBO, RTW Investments
Tej Panesar, Investment Director, Life Sciences, British Patient Capital
Hubert Birner, Managing Partner, TVM Capital

William Hicks, Partner, Mintz Levin    Sofia Ioannidou, Partner, Andera Partners    Stephanie Sirota, Partner and CBO, RTW Investments    Tej Panesar, Investment Director - Life Sciences, British Patient Capital    Hubert Birner, Managing Partner, TVM Capital Life Sciences 300x


De-Risk Investments And Increase ROI Through Strategic VC CDMO Collaboration

Early stage investment in biotech is high risk due to the low probability of candidate success and increasing competition globally. Lonza has developed a unique business model to partner with VCs, supporting them in de-risking their investments by offering due diligence support and can increase ROI through proven, scalable development and manufacturing solutions for their product supply.

  • Partnering with a CDMO which takes a holistic approach to drug substance and drug product development
  • How Portfolio companies can simplify their supply chain, resulting in a shortened development timeline
  • Minimizing risks and reducing process complexity

Pnina Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza

Pnina Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza


Striving For Progress In Diversity & Inclusion

Diversity is strength. Whether gender, ethnicity, or socio-economic background, in an industry that solves complex challenges it is the organisations and companies who have a variety of ideas, experiences, and mindsets that will be the most robust, resilient, and successful. Despite some improvements, there is a long way to go to in a truly equitable environment, and investment in terms of capital to more diverse organisations, but also time and focus is, needed to redress the imbalances. A multi-stakeholder panels discusses how the industry is faring, and what more of it should be doing, in championing Diversity, Equity and Inclusion (DEI).

  • The key role of investors leading the way and providing equitable access to funding and resources
  • Prioritising DEI - practical steps investors, companies and the industry can take to make a difference
  • The importance of collecting data, considering metrics and taking learnings from them

Moderator: Ian Coyne, Executive Director Global Information & Intelligence, Coulter Partners
Priya Mande, CEO, PsiOxus Therapeutics
Rhoda Steel, Head of Community Impact, Johnson & Johnson UK
Anya Roy, Head of Seed Investments & Technology, Illumina Accelerator

Ian Coyne, Consulting Partner, Coulter Partners    Priya Mande, CEO, PsiOxus Therapeutics    Rhoda Steel, Head of Community Impact, Johnson & Johnson UK    Anya Roy, Head of Seed Investments & Technology EMEA, Illumina


Partnerships & Deal Making


The New (And Improved) Normal - Building A More Connected European Ecosystem

After a period of enforced isolation, rather than a breakdown in communication many found efficiencies in the virtual world. As we get back to the ‘new normal’, how can Europe work to make this an improved normal, with a less fragmented and more collaborative ecosystem? Heads of leading life science hubs building cross-geography partnerships to build an even more robust European ecosystem.

  • How are leading life science clusters working to build and develop and ensure success for innovators in their region?
  • Cultural, incentive and structural differences across the continent
  • Ideas and models for pan-European collaboration

Moderator: Madeleine Armstrong, News Editor, Evaluate
Bonnie Van Wilgenburg, Principal, Monograph Capital Partners
Michael Altorfer, CEO, Swiss Biotech Association 
Viola Bronsema, CEO, BIO Deutschland 
Anette Steenberg, CEO, Medicon Valley Alliance 

Madeleine Armstrong, News Editor, Vantage   Bonnie Van Wilgenburg, Principal, Monograph Capital Partners    Michael Altorfer, CEO, SwissBiotech 300x    Viola Bronsema, CEO and Secretary General, BIO Deutschland    Anette Steenberg, CEO, Medicon Valley Alliance


Moving The Needle - Successful Business Models At The Interface Between Industry, Academia And Investment

The pace of innovation in biotech and life sciences is only increasing and keeping at the cutting edge of new discoveries and next generation technologies is key. Pharma and investors are looking ever earlier to help support these ideas, alongside TTOs and accelerators, to translate early innovation into viable start-ups which can in turn then get treatments and technologies from the lab to the bedside as quickly as possible. A multi-stakeholder panel discusses evolving businesses models, stories of success, and how the whole ecosystem can work more effectively together.

  • How to get new technology into commercially viable entities more quickly
  • Learning from the successes in the UK ecosystem and how these models can be implemented in other clusters
  • What more needs to be done to expedite translation of innovation?

Bill Haynes, Head of Novo Nordisk Research Centre Oxford, Novo Nordisk 
Anne Horgan, Partner, Cambridge Innovation Capital
Dima Kuzmin, Managing Director, 4BIO Capital 
Jason Mellad, CEO, Start Codon

Bill Haynes, Head of Novo Nordisk Research Centre Oxford, Novo Nordisk    Anne Horgan, Partner, Cambridge Innovation Capital    Dima Kuzmin, Managing Director, 4BIO Capital    Jason Mellad, CEO, Start Codon

 


Capital Deployment & Commercialisation Strategy


The Future Of The Emerging Biopharma Launch Landscape

  • Overview of the first-launch landscape - reviewing novel first launches in Europe and the US in the last decade
  • Best practices for first launches for COVID and beyond
  • Recent trends in launches with a spotlight on cell and gene therapy and oncology
  • What can we expect to see in the next 5 years in the emerging biopharma launch landscape?

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates 

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates


Challenges And Operational Scale Up For First Product Launch

Navigating the ‘go-it-alone’ strategy is a huge financial, operational, and structural undertaking. However, as the industry grows, evolves and matures, and with more capital in the space than ever before, first launches by emerging biopharma are becoming more commonplace - first launches have made up more than a quarter of all new molecules submitted to the FDA since 2016. Executives discuss…

  • What does it take to build, scale and prepare your company for launch?
  • Exit valuations after commercialisation compared with a late stage partnering strategy
  • Key success factors and considerations in a first launch and evolving into a commercial company

Moderator: Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates 
Dick Sundh, VP, Head of Australia, Canada & Europe, Kite
Christina Rossi
, Chief Commercial Officer, Blueprint Medicines

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates    Dick Sundh, VP, Marketing & Head of Australia, Canada and Europe (ACE), Kite Pharma    Christina Rossi, Chief Commercial Officer, Blueprint Medicines


Business Models For Cell & Gene Therapy: Evolution Or Revolution From The Existing Biopharma Model?

The advent, development and commercialization of new technologies entails the development and refinement of new business models that allows companies to create, deliver and capture value. Cell and Gene Therapy (CGT) is an exciting frontier in in therapeutics and capital investments are fuelling rapid scientific innovation and providing the opportunity for biotechs to commercialize themselves. However, there are several challenges associated with the CGT business models and some of these vary depending on the therapeutic modality and disease area being targeted. Industry leaders have long been talking about shifting from becoming a supplier of therapeutic products to delivering ‘value’ in the form of patient outcomes – CGT could be seen as a catalyst and accelerator of this change. But will this change require companies to evolve or create new business models?

  • Which components of the biopharma business model are largely impacted by CGT? – value capture, value delivery or value creation
  • What does the future of CGT look like?
  • How does the system need to evolve for future commercial sustainability?
  • What are key capabilities that companies need to invest in to succeed in the future world?
Moderator: Maya Khurana, Health and Life Sciences Director, Oliver Wyman
Olav Hellebo
, CEO, ReNeuron
Jean-Philippe Combal
, CEO, Vivet Therapeutics
Lucas de Breed
, Founder, August

Maya Khurana, Health and Life Sciences Director, Oliver Wyman    Olav Hellebo, CEO, ReNeuron Group    Jean-Philippe Combal, CEO, Vivet Therapeutics    Lucas de Breed, Founder, August

 


Lunch Break


Capital Markets & Investment


Sourcing And Funding Next Generation Innovation

With more capital available for early-stage companies than ever before, how are investors sourcing the latest innovations with larger rounds, bigger and more diverse syndicates? What are their focus areas and how are they sourcing the latest discoveries and technological advances that will be the next wave of biotech leaders? As focus switches back from pandemic treatments and solutions, panel of early-stage investors discuss the early- landscape and what’s exciting them in 2022.

  • Will we continue to see investors back the best companies with increasingly larger seed and series A funding rounds to give young companies a stronger runway?
  • Geographical syndication – are early-stage investors seeing greater global interest in syndication opportunities?
  • In the ‘Golden Age of Biotechnology’ we are in, which next generation tech is exciting investors?


Moderator: Samana Brannigan, Head of Health Technologies, Innovate UK 
Diana Torgersen, Senior Associate, Novo Seeds 
Edward van Wezel, Managing Partner, BGV 
Roel Bulthuis, Managing Director, INKEF Capital 
Mehdi Ainouche, Principal, Jeito
Alex Hamilton, Partner, Syncona

Samana Brannigan, Innovation Lead and Investor Relations, Innovate UK 300x    Diana Torgersen, Senior Associate, Novo Seeds    Edward van Wezel, Managing Partner, BGV    Roel Bulthuis, Managing Director, INKEF Capital    Mehdi Ainouche, Principal, Jeito    Alex Hamilton, Partner, Syncona


Preparing For And Protecting Your Assets When Entering The US

Entering the US market can be a challenge, but it is becoming a strategic consideration ever-earlier in the growth process for many companies. Asset protection when entering a new market is the key to long-term success and includes securing capital from investors, preparing for licensing and transactions, and minimizing litigation risk. Efficient and effective due diligence can protect your assets and save you time, money and headaches further down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their intellectual property portfolios for entry to the US.

  • How investors analyse, identify and mitigate risk in investing in life science companies seeking to market in the US
  • How to put yourself in the best possible position for investment and deals
  • What assets investors and partners will want to see in your intellectual property portfolio
  • How to protect privileged and confidential information during the due diligence process

Moderator: Gwilym Attwell, Principal, Fish & Richardson
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly
Pierre-Louis Joffrin, CDO, Mogrify
Robin Bhattacherjee, CEO, Actimed

Gwilym Attwell, Principal, Fish & Richardson    Tim Luker, VP Venture Science, Corporate BD, Eli Lilly    Pierre-Louis Joffrin, CDO, Mogrify    Robin Bhattacherjee, CEO, Actimed Therapeutics


Partnerships & Deal Making


Making A Mark - Emerging Players In Biotech Deals And Acquisitions

While the world’s largest pharma companies often dominate headlines with large ‘biobucks’ licencing agreements and M&A mega deals, a growing number of smaller pharma companies are also hungry for partnerships, deals and acquisitions. Heads of BD & M&A and emerging deal-makers at growing pharma share their strategies, focus areas and how they are looking to make their mark in the biopharma landscape:

  • Finding the right partners and in dedicated ecosystems
  • Smaller pharma’s partnering and deal making strategies in a competitive market
  • Strategic alignment - key therapeutic areas of interest

Jukka Muhonen, Global BD & Alliances, Orion Pharma
Paolo Cionini, Chief Commercial Officer, Amirall
Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma 
Steven Harris, Chairman, CS Pharmaceuticals

Jukka Muhonen, Director of Global Business Development and Alliance Management, Orion Corporation    Paolo Cionini, Chief Commercial Officer, Almirall    Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma    Steven Harris, Chairman, CS Pharmaceuticals


Competition Intensifying? China’s Partnering And Deal Making Strategies

Records levels of cross-border licensing partnerships have been agreed between multi-national Pharma and Chinese companies through 2020 and 2021. Deals boomed both for Pharma acquiring or partnering on innovative Chinese assets as well as Chinese companies developing and commercialising drugs for Western companies. While capital is still awash in China, this increased activity has meant a more competitive landscape - has sourcing and building win-win deals become ever harder? Executives discuss the booming Chinese partnering and deal-making landscape.

  • Will the growth in cross-border transactions with Chinese companies continue?
  • In a more global competitive market for deals, how are strategies evolving?
  • What are Chinese companies looking for in deals?

Guillaume Vignon, SVP BD, Beigene 
Yuehua Cong, Executive Director, Head of Europe, Simcere Pharmaceutical Group
Maria Dahl, COO and Head of Europe, Innovent Bio
Donald Xu, Managing Director, Lynx Capital

Guillaume Vignon, SVP BD, Beigene    Yuehua Cong, Executive Director, Head of Europe, Simcere Pharmaceutical Group    Maria Dahl, COO and Head of Europe, Innovent Bio    Donald Xu, Managing Partner, Lynx Financial

 


Capital Deployment & Commercialisation Strategy


A Platform For Success – Strategic Imperatives In Building And Growing Discovery Platforms

After two decades of venture investors primarily funding product-centric companies, now newly hatched companies with disruptive drug discovery platforms but no identified lead assets are raising historically unprecedented financings. Platform companies face numerous strategic development challenges prior to and beyond the point at which the value of tangible product assets ultimately takes over as the principal valuation driver. The rewards of developing a compelling corporate development strategy can be considerable, since strategically developed platforms are capable of generating enterprise value both more rapidly and expansively than conventional “phase transition” asset development. Early-stage investors and platform company CEOs discuss the strategic imperatives in extracting optimal near and long-term value from discovery platforms.

  • Determining and executing near-term preclinical studies
  • Selecting and prioritising therapeutic area(s), disease(s) and indication(s)
  • Taking a portfolio approach to platform vs target risk
  • Developing a proactive strategy to utilize partnering as a strategic value multiplier

Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting
John Orwin, CEO, Atreca

Ed Saltzman, Executive Chairman, Cello Health BioConsulting 300x    John Orwin, CEO, Atreca

 


Afternoon Break


Rebounding, Rebuilding, Reimagined – Pharma Bd & M&A Outlook In 2022 And Beyond

Whilst somewhat dampened through 2020, there are predictions of extensive M&A activity through 2021 and in 2022 as beyond as in-person deal-making returns and the industry rebounds. Both ‘mega-mergers’ and smaller bolt on deals to supplement pipelines and get cutting edge innovations to patients faster are slated, though with a backdrop of increased scrutiny of larger deals and an increasing diversity in innovation across the healthcare sector. Are Pharma’s strategies evolving and can we expect an increasingly active market? Leading global deal-makers discuss how M&A activity will evolve in the biopharma industry.

  • With competition authorities increasingly looking at complex M&A activity, what kind of difference could this make to the pharma industry?
  • Will smaller bolt-on acquisitions continue as a key engine for driving growth?
  • Will oncology continue to dominate deal-making? Which other new technology innovations are the world’s largest companies looking at with most interest?

Moderator: Robbie McLaren, Partner and Vice Chair of the Global Life Sciences Practice, Latham & Watkins
Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA 
Nigel Sheail, Global Head of M&A and BD&L, Novartis

Robbie McLaren, Partner, Latham & Watkins    Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA    Nigel Sheail, Global Head of M&A, Business Development & Licensing, Novartis


Personalised Medicine And The Importance Of High-Quality Health Data At Scale

The complexity of human biology is staggering - every person, and pretty much every disease, is unique. The digital revolution in healthcare is providing new ways to collect high-quality anonymised data from each person and connect it to data from large pools of other individuals for analyses, using both conventional and artificial intelligence-based algorithms. This will drive a deeper understanding of how to develop targeted therapeutics and diagnostics, ensuring the right treatment for the right patient at the right time. This session will discuss the importance of partnering with governments, patients, clinicians, companies and academia, to collect, curate, make available and analyse high-quality anonymised "data-at-scale" to provide improved and personalised care for everyone across their entire healthcare journey.

Anna Williamson, Executive Director, Roche Pharma Partnering

Anna Williamson, Senior Director, Business Development, Roche


Networking Party

Wednesday 11 May 2022
(All times in GMT)


Welcome Address

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX


Go West! – Considerations For US IPOs And Dual Listings

After a record-breaking year in 2020, the IPO market has slowed in 2021. For European companies, what remains is the stark contrast in terms of listings on local European exchanges compared to what is now a well-trodden route to Nasdaq. The huge amount of capital available in the US has long provided a pull for European biotechs and with healthcare in general brought to the fore more than ever before in 2020, many companies took advantage of the open IPO window to list or dual-list in the US. A major consideration for any company, executives who have taken their businesses public in the US discuss the decision and timing their listing, how they managed during in a period of huge disruption and travel restrictions and key success factors in taking European companies to Nasdaq.

  • Key considerations for companies looking to tap the US public markets
  • What skills and experience are necessary to bring on to your board and management team for life on US public markets?
  • The European discount – is perception of European companies being undervalued (or US companies overvalued) a reality?
  • Has the biotech IPO market peaked? Is the window closing?

Isabella Schidrich, Senior Managing Director, Nasdaq
Berndt Modig, CEO, Pharvaris
Florian Brand, CEO, ATAI Life Sciences
Mai-Britt Zocca, CEO, IO Biotech
Steve Hurly, CEO, Lava Therapeutics

Isabella Schidrich, Managing Director, NASDAQ    Berndt Modig, CEO, Pharvaris    Florian Brand, CEO, ATAI Life Sciences    Mai-Britt Zocca, CEO, IO Biotech    Steve Hurly, CEO, Lava Therapeutics


Morning Break


Capital Markets & Investment


SPACS – Are They Here To Stay And How Will They Evolve?

Whilst blank cheques are not a new vehicle, SPACs in biotech and healthcare have exploded and been the hottest trend in the sector. There is much debate around the pros and cons, with SPACs allowing the ability to merge crossover rounds with the IPO into one step and giving speed to market for the companies, but many, including at Pharma, have reservations. Are SPACs here to stay in the life science industry for the long term? Experts and SPAC sponsors discuss the recent boom, the future of the vehicles in the space and how the products could evolve moving forward

  • What are the pros and cons for companies considering a SPAC compared to a traditional IPO?
  • What makes a company attractive for a de-SPAC merger?
  • Are these vehicles, which have exploded in the US, to become increasingly commonplace in Europe?

Eduardo Bravo, CEO, EBAC (European Biotech Acquisition Corporation)
Jim Polson, Managing Director, FTI Consulting
Jasper Bos, General Partner, Forbion; CEO, Forbion European Acquisition

Eduardo Bravo, CEO, EBAC (European Biotech Acquisition Corporation)    Jim Polson, Managing Director, FTI Consulting    Jasper Bos, General Partner, Forbion; CEO, Forbion European Acquisition


Continuation Or Cool Off…A Reckoning Looms? - Assessing The Booming Public Markets

The pandemic-caused global recession passed biotech by, with Investment and funding reaching record levels including an explosion of IPOs, SPACs and follow-ons. The question now becomes, is the current public markets environment sustainable? While current conditions remain very healthy, how big is the risk of the bubble bursting? Fund managers and analysts debate the future of the capital markets.

  • While 2021 was not quite the same as 2020, the public markets environment remains robust – how long will this last?
  • The impact and risks of deep-pocketed new entrants to healthcare investment
  • What are the drivers for continued optimism, and what are the risks that could result in a cool-down?

Geraldine O’Keeffe, General Partner, LSP 
Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience 

Geraldine O’Keeffe, Partner, LSP    Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience


Partnerships & Deal Making


Go-To-Market Strategies Across Geographies And Overall Equity Returns

Biotech companies’ commercial planning should be starting earlier and earlier as industry dynamics shift. A key consideration will be the strategy around commercialising in different geographies and potential partnerships in licencing or co-promotion. But how do these decisions affect overall equity returns? After a presentation of in-depth analysis to date, executives and investors discuss:

  • Developing a global commercial strategy and considerations for commercialisation rights
  • Going alone or licencing or co-promoting across different geographies and how that impacts overall equity value
  • Analysing the importance of retention of commercialisation rights in different geographies
  • Investor perspectives on biotech’s commercial strategies

Presenter and moderator: Cody Powers, Principal - Portfolio & Pipeline, ZS Associates
Peter Llewellyn-Davies, CEO, APEIRON 
Karl Nägler, Managing Partner, Wellington Partners
Erik van den Berg, CEO, AM Pharma
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics

Cody Powers, Principal - Portfolio & Pipeline, ZS Associates    Peter Llewellyn-Davies, CEO, APEIRON    Karl Nägler, Managing Partner, Wellington Partners    Erik van den Berg, CEO, AM Pharma    Renee Aguiar-Lucander, CEO, Calliditas Therapeutics


Finding The Fit - Win-Win Deals In Pharma Partnering

As the pace of innovation across the healthcare space increases, pharma are ever-more active in scouting for early and later stage deals The expertise, resources and connections of industry giants remains critical, but in a sector awash with capital and with increased competition, are strategies changing? Pharma S&E and BD executives discuss how they are supporting innovation, going earlier in building their pipelines, and the increasingly competitive landscape for attractive deals.

  • "Earlier and earlier" cried Alice in Pharmaland - how are the industry biggest players looking to source innovation sooner and support the youngest startups?
  • Is it more competitive than ever before?
  • What are the key considerations for companies in their partnering strategy approaching pharma, and are most commonly overlooked?
  • Which type of partnering at which stage?

Khatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSD 
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly
Marta Helena Lesko, Head of BD Enabling Technologies, Merck KGaA 
Markus Kalousek, Global Head Search & Evaluation, Novartis

Khatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSD    Tim Luker, VP Venture Science, Corporate BD, Eli Lilly    Marta Helena Lesko, Head of BD Enabling Technologies, Merck KGaA    Markus Kalousek, Global Head of Pharma S&E, Novartis


Capital Deployment & Commercialisation Strategy


Managing Risk In The New World – Security, Data, Resilience In The Biopharma Supply Chain

The last 24 months have been quite historic for organisations within the life sciences and healthcare industries. In addition to the obvious global COVID-19 response, businesses have continued to grow and evolve in cyber terms. Whether it be innovations in cyber-enabled treatments or therapies, or making the best use of technology to support efficient delivery of organisational objectives and business strategies, one thing is clear – the industry is at the very forefront of the cyber operating environment. With this level of innovation, the heightened degree of interaction within the cyber space, and in considering the ‘data heavy’ and highly regulated nature of the industry, all against a backdrop of growing and emerging cyber threats, it is crucial that life science sand healthcare organisations of all types view cyber risk as being amongst, if not the, biggest risks to their businesses.

  • What does the cyber threat landscape look like for this industry?
  • Have cyber security practices kept pace with innovation and the implementation of new technologies?
  • Is the convergence of the physical and virtual domains fully understood by this industry, and what are the risks in this space?
  • How can organisations better protect themselves in the now, and what or where should they focus their efforts in looking ahead?

Moderator: Dean Chapman, Director (People + Cyber Solutions), Willis Towers Watson

Dean Chapman, Director (People + Cyber Solutions), Willis Towers Watson


Dressing For Success Early As A Biopharma Startup

Pre-Clinical biopharma start-ups often don’t have time to rest – always needing to propel their organization to their next phase of development. But what that next phase of development looks like uniquely to that organization is often unclear and when do they need to ‘dress’ for it are common questions. Identifying the structural, technical, and development challenges to plan for in trying to get to the next level are widely complex. In this panel, hear from newly formed companies and how they worked through their planning process and set themselves up for their next phase of growth, issues they faced along the way, and the realities they face as a start-up.

Moderator: Matt Cardinal, VP Strategy & Program Leadership, Halloran
Ros Deegan, CEO, OMass Therapeutics
Valerie Vanhooren, CEO & Co-Founder, ONA Therapeutics
João Siffert, CEO & President, Design Therapeutics
Suzanne Dilly, CEO, ValiRx

Matt Cardinal, Principal, Halloran Consulting Group 300x    Ros Deegan, CEO, OMass Therapeutics    Valerie Vanhooren, CEO, ONA Therapeutics    João Siffert, CEO & President, Design Therapeutics    Suzanne Dilly, CEO, ValiRx


Multi-Jurisdictional Drug Development

The pandemic had ripple effects throughout the healthcare industry, one of which being regulatory healthcare authorities undergoing their own adaptation and changes. A lot more communication between regulators in different geographies is now more common, with a lot more sharing of information. Experts and companies who are undertaking and multi-jurisdictional drug development discuss what this means for companies and the wider industry post-covid.

  • Navigating drug development strategy across the FDA, EMA, MHRA and other regulatory bodies
  • Key success factors in targeting multiple jurisdictions at the same time
  • Starting early and with the end in mind whilst avoiding common pitfalls and bottlenecks

Moderator: Laurie Smaldone Alsup, Chief Medical and Scientific Officer, NDA
Steffen Thirstrup, Advisory Board Director, NDA Group

Laurie Smaldone Alsup, CMOCSO, NDA Group    Steffen Thirstrup, Advisory Board Director, NDA Group


Lunch Break


Fireside Chat: Realising Opportunities And Potential In Cell & Gene Therapies

Sofia Håkansson Buch, VP Stem Cell CMC & Manufacturing, Novo Nordisk

Sofia Håkansson Buch, VP Stem Cell CMC & Manufacturing, Novo Nordisk


Shaping The Future Of Advanced Therapies - Time To Deliver And Realise Full Value?

The promise and hype of advanced therapies is finally translating into a reality and represents the next major wave of therapeutics. With mRNA vaccines playing a lead role in the fight against COVID-19 providing further optimism and validation, Pharma and biotech have burgeoning pre-clinical and clinical pipelines across various therapeutic areas - over 60 C&GT products have been approved worldwide and there are around 2,000 open or planned clinical trials. With huge increases in investment and M&A activity is in the space, the future of cell and gene therapies is bright, but many challenges remain – what is the future of advanced therapies, and how are companies working to expedite getting this technology from bench to bedside?

  • While oncology still dominates, which other therapeutic areas are showing promise?
  • Clinical challenges - limited sites performing perform C&GT trials effectively, patient recruitment and long-term follow-up
  • Manufacturing challenges - time, labour intensive and expensive processes, supply chain risks, achieving commercial scale
  • Reimbursement and commercialisation challenges - high costs and proving value, obtaining reimbursement across geographies, public misinformation

John Dawson, CEO, Oxford BioMedica
Sven Kili, CEO, Antion
Nicoletta Loggia, CTO, Orchard Therapeutics
Jason Foster, CEO, Ori Biotech

John Dawson, CEO, Oxford Biomedica    Sven Kili, CEO, Antion    Nicoletta Loggia, CTO, Orchard Therapeutics    Jason Foster, CEO, Ori Biotech


Making The Undruggable, Druggable - The Exciting Potential Of Targeted Protein Degradation

The concept of targeted protein degradation presents revolutionary drug development opportunities and, similar to technology innovations which have come before like gene-editing, is anticipated to bring about a paradigm shift in modern healthcare in the coming years. As the TPD field grows, with increased investment and more Pharma programmes, new companies emerging with new approaches and assets entering the clinic, executives discuss this new frontier of medicine, and what is needed to realise its full potential.

  • What are the limitations of existing TPD approaches, and what could the next generation look like?
  • Do TPD drugs have the potential to be the next blockbusters?
  • What are the key challenges in the TPD field? Which key factors that are likely to influence the evolution the area?

Dan Marshall, Director Business Development, MSD
Tom Shepherd, CEO, Captor Therapeutics
Christian Dillon​, CSO, Phoremost

Dan Marshall, Director Business Development, MSD    Tom Shepherd, CEO, Captor Therapeutics    Christian Dillon​, VP Biology, Phoremost

 

DOWNLOAD BROCHURE